Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

Background Circulating tumor cells (CTCs) and chemokine (C-X-C motif) receptor 4 (CXCR4) expression in CTCs and tumor tissue were evaluated as prognostic or predictive markers of CXCR4 peptide antagonist LY2510924 plus carboplatin-etoposide (CE) versus CE in extensive-stage disease small cell lung c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Salgia, Ravi, Weaver, R. Waide, McCleod, Michael, Stille, John R., Yan, S. Betty, Roberson, Stephanie, Polzer, John, Flynt, Amy, Raddad, Eyas, Peek, Victoria L., Wijayawardana, Sameera R., Um, Suzane L., Gross, Steve, Connelly, Mark C., Morano, Carrie, Repollet, Madeline, Sanders, Renouard, Baeten, Kurt, D’Haese, David, Spigel, David R.
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2017
Matèries:
Phase II Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5418321/
https://ncbi.nlm.nih.gov/pubmed/28299514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0446-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars